AbbVie (ABBV) FCF Payout Ratio (2013 - 2026)
AbbVie's (ABBV) quarterly FCF Payout Ratio came in at 0.99 in Q2 2026, up 65.46% year-over-year from 0.6 in Q2 2025, and up 13.86% quarter-over-quarter from 0.87 in Q1 2026.
Analysis
AbbVie (ABBV) FCF Payout Ratio (2013 - 2026) Analysis & Trends
AbbVie (ABBV) has reported FCF Payout Ratio for 14 consecutive years, with 0.99 the latest figure, recorded in Q2 2026.
- On a quarterly basis, FCF Payout Ratio rose 65.46% year-over-year to 0.99 in Q2 2026; TTM through Jun 2026 was 0.66, a 5.81% increase from a year earlier, with the FY2025 full-year figure at 0.65, up 5.83% from the prior year.
- FCF Payout Ratio was 0.99 for Q2 2026 at AbbVie, up from 0.87 in the prior quarter.
- Over five years, FCF Payout Ratio peaked at 2.09 in Q1 2025 and troughed at 0.34 in Q3 2022.
- A 5-year average of 0.69 and a median of 0.55 in 2022 frame the typical range for FCF Payout Ratio.
- Across the five-year window, FCF Payout Ratio jumped 216.92% in 2024 and tumbled 58.56% in 2026, its largest moves.
- Over 5 years, FCF Payout Ratio stood at 0.35 in 2022, then soared by 66.24% to 0.58 in 2023, then slipped by 29.46% to 0.41 in 2024, then surged by 46.19% to 0.6 in 2025, then soared by 65.58% to 0.99 in 2026.
- The last three FCF Payout Ratio figures came in at 0.99 (Q2 2026), 0.87 (Q1 2026), and 0.6 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 0.44 |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 0.99 |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 0.48 |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 0.46 |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 8.12 |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 1.77 |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | - |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.99 |
| Mar 31, 2026 | 0.87 |
| Dec 31, 2025 | 0.60 |
| Sep 30, 2025 | 0.44 |
| Jun 30, 2025 | 0.60 |
| Mar 31, 2025 | 2.09 |
| Dec 31, 2024 | 0.41 |
| Sep 30, 2024 | 0.53 |
| Jun 30, 2024 | 1.35 |
| Mar 31, 2024 | 0.72 |
| Dec 31, 2023 | 0.58 |
| Sep 30, 2023 | 0.36 |
| Jun 30, 2023 | 0.43 |
| Mar 31, 2023 | 0.66 |
| Dec 31, 2022 | 0.35 |
| Sep 30, 2022 | 0.34 |
| Jun 30, 2022 | 0.52 |
| Mar 31, 2022 | 0.53 |
| Dec 31, 2021 | 0.47 |
| Sep 30, 2021 | 0.30 |